

For Public Release

NZX Limited
Wellington

14 September 2022

Notification of Issue of Securities

Please find attached the Capital Change Notice regarding the issue of ordinary shares.

This notice relates to CBD's recent Rights Issue and Oversubscription Bookbuild Capital Raise Offer that raised a total of \$3,180,186 through the issue of 10,600,621 new ordinary fully paid shares.

The final allotment report confirms the below breakdown:

Entitlement Shares	5,062,994 @ \$0.30 cents
Oversubscription Bookbuild Shares	5,537,627 @ \$0.30 cents
Total Funds Raised	\$3,180,186

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products will be produced under GxP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd, and Midwest Pharmaceuticals NZ Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>